PMC:7497282 / 104986-105779 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7497282","sourcedb":"PMC","sourceid":"7497282","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7497282","text":"Modeling studies will need to reevaluate the health and economic impacts of the GPEI, if it succeeds, and evaluate the costs and benefits of future poliovirus vaccine options. In the case of a successful OPV cessation, all countries will realize the benefits of a world free of WPVs and cVDPVs, and determine their interest in purchasing the long-term insurance offered by IPV use. We expect that high- and upper middle-income countries will continue to use IPV and increasingly use IPV-containing combination vaccines, albeit at relatively high costs [240]. We also anticipate a continued trend toward the use of IPV-only schedules by these countries, although as long as LPVs continue to circulate, countries at risk of LPV importation will likely continue with sequential IPV/OPV schedules.","tracks":[]}